Undifferentiated Ovarian Carcinoma Recruiting Phase 1 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028876 (Undifferentiated Ovarian Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02020707Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological CancersTreatment